ASCO Abstracts 2020

 

ASCO Abstracts

 


ASCO: Phase III QUAZAR AML-001 trial

 

Abstract No : 7530

Abstract Type : Poster Discussion Session

Indication : Acute Myeloid Leukemia

Intervention : CC-486

Company : BMS

Technology : Small molecule

CC-486 is safe and well-tolerated as maintenance therapy in elderly patients ($75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.

 

ASCO: KEYNOTE-189 study

 

Abstract No : 9582

Abstract Type : Poster Session

Indication : Nonsquamous NSCLC

Intervention : Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro)

Company : Merck Sharp & Dohme Corp.

Technology : Monoclonal antibody

Final data of KEYNOTE-189 study in patients with newly diagnosed metastatic nonsquamous NSCLC

 

ASCO: Initial KarMMa results

 

Abstract No : 8503

Abstract Type : Oral Abstract Session

Indication : Multiple Myeloma

Intervention : Idecabtagene vicleucel

Company : Bristol-Myers Squibb and bluebird bio.

Technology : CAR T Cell Therapy

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results

 

Anti-cd47 Antibody Magrolimab Combined With Azacitidine

 

Abstract No : 7507

Abstract Type : Poster Discussion Session

Indication : MDS/AML

Intervention : Magrolimab

Company : Forty Seven, Inc

Technology : Monoclonal antibody

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results

 

 

Comments

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

Cervical Intraepithelial Neoplasia Market and Epidemiology 2032 by DelveInsight

The Need And The Importance Of The Healthcare Reports for the Pharma Companies